Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application

Stock News

09/10

Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.

Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.

This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1185698776"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185698776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185698776?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185698776","market":"sg","top_or_hot":-1,"title":"Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application","media":"Stock News","content":"<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.<br><br>Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.<br><br>This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-10 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.<br><br>Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.<br><br>This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1185698776","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185698776","pubTimestamp":1789040057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","BK0028":"国家队","BK0239":"医药制造","000931":"中关村","BK0178":"特色小镇","BK0075":"新三板"},"translate_title":"北京盛捷科技替格瑞洛片上市申请获国家药监局受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000931":1,"IPOS":1},"content_text":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}